Article
Comparative Immune profiling in Pancreatic Ductal Adenocarcinoma Progression Among South African patients
2023-10-23
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Introduction</h4> Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive cancer with a 5-year survival rate of only 11%. PDAC is characterized by an immunosuppressive microenvironment; thus, there have been multiple attempts to target it, although with little success. A better understanding of the immune landscape in PDAC is required to help elucidate the roles of these cells for effective...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a6f15597-28dc-5eea-b4b5-a334aebb462f
- DOI
- 10.1101/2023.10.23.23297385
